|Day's Range||29.360 - 30.050|
|52 Week Range||29.360 - 56.440|
|PE Ratio (TTM)||377.18|
|Dividend & Yield||1.36 (4.55%)|
|1y Target Est||N/A|
Commenting on Mylan N.V. (NASDAQ: MYL ), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. ...
Billionaires appear to have focused on drug stocks that were mired in debt in Q1.
This very blog has offered up no shortage of opinions on shares Valeant Pharmaceuticals International (VRX)...some good, some bad and some still undecided. Quoting from Gilbert’s recent note, StreetInsider reported: We have been cautious/skeptical on VRX for a very long time, and uncertainties around the growth potential and durability of key franchises, the potential cost of past sins, and the heavy debt load have kept us at Hold.